Sectors
ATRA
Atara Biotherapeutics, Inc.
8.28
1 x 8.29
1 x 8.64
bid
ask
-
0.35
4.05%
10:00 AM
timesize
| Ytd | -54.23% | |
| 1y | -36.40% |
8.61
day range
8.61
3.92
52 week range
19.14
| Open | 8.61 | Prev Close | 8.63 | Low | 8.61 | High | 8.61 | Mkt Cap | 77.76M |
| Vol | 6.54K | Avg Vol | 1.43M | EPS | -0.67 | P/E | -12.88 | Forward P/E | -1.52 |
| Beta | 0.08 | Short Ratio | 7.11 | Inst. Own | 50.82% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 9.87 | 200-d Avg | 9.70 | 1yr Est | 16.33 |
| Income Statement | |||
| Total Revenue | 516.00K | ||
| Revenues (USD) | 516.00K | ||
| Cost of Revenue | 124.00K | ||
| Gross Profit | 392.00K | ||
| Operating Expenses | 3.76M | ||
| Research and Development Expense | 164.00K | ||
| Selling, General and Administrative Expense | 3.60M | ||
| Operating Income | -3.37M | ||
| Interest Expense | 830.00K | ||
| Net Income | -4.14M | ||
| Net Income Common Stock | -4.14M | ||
| Net Income Common Stock (USD) | -4.14M | ||
| Consolidated Income | -4.14M | ||
| Earnings per Basic Share | -0.29 | ||
| Earnings per Basic Share (USD) | -0.29 | ||
| Earnings per Diluted Share | -0.29 | ||
| Earning Before Interest & Taxes (EBIT) | -3.31M | ||
| Earning Before Interest & Taxes (USD) | -3.31M | ||
| Weighted Average Shares | 14.08M | ||
| Weighted Average Shares Diluted | 14.08M | ||
| Balance Sheet | |||
| Cash and Equivalents | 8.36M | ||
| Cash and Equivalents (USD) | 8.36M | ||
| Current Assets | 12.17M | ||
| Property, Plant & Equipment Net | 6.93M | ||
| Total Assets | 20.00M | ||
| Debt Current | 715.00K | ||
| Total Debt | 50.55M | ||
| Current Liabilities | 5.65M | ||
| Debt Non-Current | 49.84M | ||
| Total Liabilities | 57.31M | ||
| Accumulated Retained Earnings (Deficit) | -2.03B | ||
| Shareholders Equity | -37.31M | ||
| Shareholders Equity (USD) | -37.31M | ||
| Assets Non-Current | 7.82M | ||
| Total Debt (USD) | 50.55M | ||
| Deferred Revenue | 684.00K | ||
| Liabilities Non-Current | 51.66M | ||
| Trade and Non-Trade Payables | 637.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 214.00K | ||
| Net Cash Flow from Financing | 2.95M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -122.00K | ||
| Issuance (Purchase) of Equity Shares | 2.95M | ||
| Net Cash Flow from Operations | -3.07M | ||
| Share Based Compensation | 749.00K | ||